Kailera Therapeutics (KLRA) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precigen is the larger company by market cap ($1.51 billion vs $1.43 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRA | PGEN |
|---|---|---|
| Share price | $11.02 | $4.21 |
| Market cap | $1.43B | $1.51B |
| 1-day change | -4.84% | +1.20% |
| YTD return | — | +0.72% |
| 1-year return | — | +8.51% |
| 5-year return | — | +9.07% |
| P/E ratio (TTM) | — | 38.27 |
| EPS (TTM) | $-4.16 | $0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | — | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $28.23 | $8.98 |
| 52-week low | $9.76 | $3.04 |
| Distance from 52-week high | -60.96% | -53.12% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +290.20% | +224.70% |
| Average volume | 1.08M | 5.68M |
| Shares outstanding | 129.85M | 358.55M |
| Employees | 145 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
KLRA vs PGEN FAQ
Which is bigger, Kailera Therapeutics or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $1.51B compared with $1.43B for Kailera Therapeutics (KLRA).
Are Kailera Therapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.